Hearn Jay Cho, MD, PhD

Hearn Jay Cho, MD, PhD, is chief medical officer at the Multiple Myeloma Research Foundation.

Articles by Hearn Jay Cho, MD, PhD

Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD

November 26th 2025

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD

ByRose McNulty,Hearn Jay Cho, MD, PhD

October 23rd 2025

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.

Hearn Jay Cho, MD, PhD

Articles by Hearn Jay Cho, MD, PhD

Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD

Latest Updated Articles

Trending on AJMC

Linking Insured Adults to Behavioral Health Care: A Cost-Saving Solution

Diabetes Tied to Increased Risk of Sudden Cardiac Death

Evaluating Adalimumab Biosimilar Switch Impact on Disease Flares, Tolerability

FDA Grants Full Approval to Pirtobrutinib for CLL/SLL

Daratumumab Offers Hope for Delaying Progression to Active MM: Peter Voorhees, MD